Terms: = Ovarian cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
67 results:
1. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Drilon A; Sharma MR; Johnson ML; Yap TA; Gadgeel S; Nepert D; Feng G; Reddy MB; Harney AS; Elsayed M; Cook AW; Wong CE; Hinklin RJ; Jiang Y; Brown EN; Neitzel NA; Laird ER; Wu WI; Singh A; Wei P; Ching KA; Gaudino JJ; Lee PA; Hartley DP; Rothenberg SM
Cancer Discov; 2023 Aug; 13(8):1789-1801. PubMed ID: 37269335
[TBL] [Abstract] [Full Text] [Related]
2. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to ovarian cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract] [Full Text] [Related]
3.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract] [Full Text] [Related]
4. Recent Updates on Structural Aspects of alk Inhibitors as an Anticancer Agent.
Ayaz MS; Bhupal R; Sharma P; Sahu A; Singh P; Gupta GD; Asati V
Anticancer Agents Med Chem; 2023; 23(8):900-921. PubMed ID: 36627781
[TBL] [Abstract] [Full Text] [Related]
5. Soy isoflavones decrease fibroglandular breast tissue measured by magnetic resonance imaging in premenopausal women: A 2-year randomized double-blind placebo controlled clinical trial.
Lu LW; Chen NW; Brunder DG; Nayeem F; Nagamani M; Nishino TK; Anderson KE; Khamapirad T
Clin Nutr ESPEN; 2022 Dec; 52():158-168. PubMed ID: 36513449
[TBL] [Abstract] [Full Text] [Related]
6. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.
Guo M; Shu Y; Chen G; Li J; Li F
Sci Rep; 2022 Nov; 12(1):20601. PubMed ID: 36446798
[TBL] [Abstract] [Full Text] [Related]
7. Targeting the alk-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.
Chu YY; Chen MK; Wei Y; Lee HH; Xia W; Wang YN; Yam C; Hsu JL; Wang HL; Chang WC; Yamaguchi H; Jiang Z; Liu C; Li CF; Nie L; Chan LC; Gao Y; Wang SC; Liu J; Westin SN; Lee S; Sood AK; Yang L; Hortobagyi GN; Yu D; Hung MC
Nat Cancer; 2022 Oct; 3(10):1211-1227. PubMed ID: 36253486
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of a novel alk/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract] [Full Text] [Related]
9. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
11. Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent ovarian cancer.
Ooyama T; Shimoji Y; Nakasone T; Arakaki Y; Taira Y; Nakamoto T; Kudaka W; Aoki Y
Anticancer Res; 2022 Jun; 42(6):3017-3022. PubMed ID: 35641257
[TBL] [Abstract] [Full Text] [Related]
12. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
Son J; George GC; Nardo M; Krause KJ; Jazaeri AA; Biter AB; Hong DS
Gynecol Oncol; 2022 Jun; 165(3):664-670. PubMed ID: 35400527
[TBL] [Abstract] [Full Text] [Related]
13. Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.
Chilimoniuk Z; Rocka A; Stefaniak M; Tomczyk Ż; Jasielska F; Madras D; Filip A
Future Oncol; 2022 Apr; 18(13):1627-1650. PubMed ID: 35129396
[TBL] [Abstract] [Full Text] [Related]
14. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous ovarian Carcinoma.
Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
[TBL] [Abstract] [Full Text] [Related]
15. High-intensity focused ultrasound ablation in the treatment of recurrent ovary cancer and metastatic pelvic tumors: a feasibility study.
Lei T; Guo X; Gong C; Chen X; Ran F; He Y; Shi Q; He J
Int J Hyperthermia; 2021; 38(1):282-287. PubMed ID: 33612045
[TBL] [Abstract] [Full Text] [Related]
16. Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
Scheepers ERM; de Rooij BH; Pijnenborg JMA; van Huis-Tanja LH; Ezendam NPM; Hamaker ME
Gynecol Oncol; 2021 Mar; 160(3):811-816. PubMed ID: 33454131
[TBL] [Abstract] [Full Text] [Related]
17. EML4-alk, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract] [Full Text] [Related]
18. Acceptability of quality indicators for the management of endometrial, cervical and ovarian cancer: results of an online survey.
Luyckx A; Wyckmans L; Bonte AS; Trinh XB; van Dam PA
BMC Womens Health; 2020 Jul; 20(1):151. PubMed ID: 32703282
[TBL] [Abstract] [Full Text] [Related]
19. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
[TBL] [Abstract] [Full Text] [Related]
20. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent ovarian cancer: a Proof-of-Concept Phase II Study.
Lampert EJ; Zimmer A; Padget M; Cimino-Mathews A; Nair JR; Liu Y; Swisher EM; Hodge JW; Nixon AB; Nichols E; Bagheri MH; Levy E; Radke MR; Lipkowitz S; Annunziata CM; Taube JM; Steinberg SM; Lee JM
Clin Cancer Res; 2020 Aug; 26(16):4268-4279. PubMed ID: 32398324
[TBL] [Abstract] [Full Text] [Related]
[Next]
